Abstracts tagged "tolerance and treatment"

Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Sander Strengholt⁶, Ryan DeMasi⁷ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
Abstract Number: 1385 • 2015 ACR/ARHP Annual Meeting
Efficacy and Tolerance of Rituximab in IgG4-Related Disease: A Retrospective Multicentric Study in 24 Patients
Mikael Ebbo¹, Aurélie Grados¹, Maxime Samson², Clarisse Carra-Dallière³, Agnieszka Pozdzik⁴, Pierre Labauge³, Sylvain Palat⁵, Jean-Marie Berthelot⁶, Jean-Loup Pennaforte⁷, Alain Wynckel⁸, Celine Lebas⁹, Thomas Quémeneur¹⁰, Karine Dahan¹¹, Jean-Jacques Boffa¹¹, Bertrand Godeau¹², Nicolas Limal¹², Franck Carbonnel¹³, Anne Herber¹⁴, Gaëlle Leroux¹⁵, Patrice Cacoub¹⁶, Alexis Mathian¹⁷, Eric Hachulla¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Jean-Robert Harle²⁰ and Nicolas Schleinitz¹, ¹Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Neurology, CHRU de Montpellier, Montpellier, France, ⁴Nephrology, Erasme Hospital, Cliniques Universitaires de Bruxelles, Bruxelles, Belgium, ⁵Service de Medecine Interne, CHU limoges, Limoges, France, ⁶Rhumatologie, CHU Nantes, Nantes, France, ⁷Internal Medicine, CHU de Reims, Reins, France, ⁸Nephrolohy, CHU de Reims, Reims, France, ⁹Nephrology, CHRU de Lille, Lille, France, ¹⁰CH Valenciennes, Valenciennes, France, ¹¹Nephrology, Tenon Hospital, Paris, France, ¹²Internal Medicine, Mondor Hospital, Creteil, France, ¹³Gastro-enterology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹⁴Gastro-enterology, CH de Chartres, Chartres, France, ¹⁵Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹⁷Internal Medecine Department, Pitie-Salpetriere Hospital, Paris, France, ¹⁸FAI²R, Hôpital Claude Huriez, CHRU Lille, LILLE, France, ¹⁹Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ²⁰Internal Medicine, Aix-Marseille Université, APHM, Marseille, France
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition with characteristic histopathological lesions. Nearly all anatomic sites can be involved with a risk of organ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].